Lantern Pharma Inc Ordinary Shares LTRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LTRN is a good fit for your portfolio.
News
-
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
-
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
-
Thinking about buying stock in Archer Aviation, Lantern Pharma, Taysha Gene Therapies, Pagaya Technologies, or Blink Charging?
-
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
-
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
-
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
-
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?
-
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
Trading Information
- Previous Close Price
- $5.46
- Day Range
- $5.42–6.04
- 52-Week Range
- $2.38–11.99
- Bid/Ask
- $5.26 / $5.85
- Market Cap
- $59.08 Mil
- Volume/Avg
- 128,985 / 338,477
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.85%
Company Profile
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group’s growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.lanternpharma.com
Comparables
Valuation
|
Metric
|
LTRN
|
PRLD
|
ERAS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.44 | 0.94 | 0.88 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
LTRN
PRLD
ERAS
Financial Strength
|
Metric
|
LTRN
|
PRLD
|
ERAS
|
|---|---|---|---|
Quick Ratio | 15.42 | 10.67 | 11.94 |
Current Ratio | 16.18 | 10.79 | 12.26 |
Interest Coverage | — | — | — |
Quick Ratio
LTRN
PRLD
ERAS
Profitability
|
Metric
|
LTRN
|
PRLD
|
ERAS
|
|---|---|---|---|
Return on Assets (Normalized) | −28.94% | −38.93% | −22.08% |
Return on Equity (Normalized) | −30.61% | −43.41% | −27.20% |
Return on Invested Capital (Normalized) | −32.03% | −42.59% | −27.50% |
Return on Assets
LTRN
PRLD
ERAS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yhrcjdpl | Zncb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rnhwbnccy | Pvcctmk | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wgfhgrpn | Bzpsbh | $97.8 Bil | |
MRNA
| Moderna Inc | Gdgchsp | Tvvs | $41.3 Bil | |
ARGX
| argenx SE ADR | Wgfdwrcd | Mvfh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Njfbgkrbw | Dyq | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Czhtcgrj | Tdkvx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Chqwvmrb | Pwldj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qdgscycvv | Mpdbdc | $12.5 Bil | |
INCY
| Incyte Corp | Wqlvnyfb | Sbtwls | $11.6 Bil |